company background image
ASCL.F logo

Ascletis Pharma OTCPK:ASCL.F Stock Report

Last Price

US$0.18

Market Cap

US$222.2m

7D

-16.5%

1Y

-13.6%

Updated

24 Nov, 2024

Data

Company Financials +

Ascletis Pharma Inc.

OTCPK:ASCL.F Stock Report

Market Cap: US$222.2m

ASCL.F Stock Overview

A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. More details

ASCL.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Ascletis Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ascletis Pharma
Historical stock prices
Current Share PriceHK$0.18
52 Week HighHK$0.27
52 Week LowHK$0.14
Beta0.57
11 Month Change11.87%
3 Month Changen/a
1 Year Change-13.56%
33 Year Change3,795.56%
5 Year Change-70.78%
Change since IPO-70.78%

Recent News & Updates

Recent updates

Shareholder Returns

ASCL.FUS BiotechsUS Market
7D-16.5%2.5%2.2%
1Y-13.6%16.1%31.6%

Return vs Industry: ASCL.F underperformed the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: ASCL.F underperformed the US Market which returned 31.7% over the past year.

Price Volatility

Is ASCL.F's price volatile compared to industry and market?
ASCL.F volatility
ASCL.F Average Weekly Movementn/a
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: ASCL.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ASCL.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013219Jinzi Jason Wuwww.ascletis.com

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

Ascletis Pharma Inc. Fundamentals Summary

How do Ascletis Pharma's earnings and revenue compare to its market cap?
ASCL.F fundamental statistics
Market capUS$222.23m
Earnings (TTM)-US$35.67m
Revenue (TTM)US$1.39m

159.6x

P/S Ratio

-6.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASCL.F income statement (TTM)
RevenueCN¥10.09m
Cost of RevenueCN¥22.72m
Gross Profit-CN¥12.63m
Other ExpensesCN¥245.84m
Earnings-CN¥258.47m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin-125.17%
Net Profit Margin-2,561.68%
Debt/Equity Ratio0%

How did ASCL.F perform over the long term?

See historical performance and comparison